Eurofarma launches innovative drug to fight obesity in Brazil and other 17 countries
Lorcaserin promotes satiety due to the selective activation of serotonin 2C receptors in the brain, which makes the person feel full while eating less. One of its chief benefits is safety, because it is not a stimulating or narcotic substance. Moreover, another differential is the fact that the patient keeps on losing weight during the treatment.
Prevalence of obesity has increased among adults, both in developed countries and in developing countries. Brazil experiences today a major obesity epidemic. Recent data indicate that 54% of Brazilians are considered to be overweight and approximately 20% considered obese. According to the Ministry of Health, 1 out of 5 Brazilians suffers with obesity. In the last 10 years, the obese population in Brazil went from 11.8% in 2006 to 18.9% in 2016, a 60% growth. This number is gets more alarming when we consider the youth population, between 18 and 24 years of age, where obesity increased 110%.1
Lorcaserin was approved in 2012 by the US Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m² (obesity) or ≥27 kg/m2 (overweight)
According to Martha Penna, Eurofarma's Innovation vice-president, the agreement with Eisai is very important to fight obesity in the country. "Our presence across Latin America, excellent performance in sales and ethic standards represented an attractive to Eisai, which will start to offer the drug to a very relevant market worldwide. For us, the marketing of Belviq® will further improve our solutions to fight obesity, besides bringing safety and convenience to physicians and patients".
The drug will arrive in Brazil in 2019, and can be bought over the counter. The novelty is part of an agreement entered into by the companies to develop and market the product in other 17 countries (Argentina, Bolivia, Central America and the Caribbean - Belize, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama -, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay, Venezuela) and Brazil was chosen as another trade point for the drug, increasing the product's presence in Latin America.
A study conducted involving 12,000 overweight and obese patients that presented atherosclerotic cardiovascular disease or multiple risk factors like hypertension and diabetes, for example, confirmed the cardiovascular safety of the treatment with lorcaserin. The study observed that the long term treatment with lorcaserin does not increase the incidence of MACE (Major Adverse Cardiovascular Events, including myocardial infarction, stroke and cardiovascular death) and the primary safety objective of the study was met. It was also demonstrated improvement in several cardiovascular risk factors, including blood pressure, lipids, blood glucose and renal function. The treatment with lorcaserin also reduces diabetes incidence risk, induces hyperglycemia remission and risk of micro vascular complications in overweight and obese patients, supporting lorcaserin role as adjunct to the change of life style to chronic control of weight and metabolic health.2
It is a modern drug with good tolerability, presenting low incidence of adverse events. The most common reported events are: headache, dizziness, fatigue, nausea, dry mouth and constipation in patients without diabetes and hypoglycemia, headache, back pain, cough and fatigue in patients with diabetes.3
There are several evidences of lorcaserin benefit in the loss of weight. A study demonstrated that patients that used lorcaserin had double chances of losing 5% of body weight, with an average of weight loss of 5.8Kg in one year.4
For further information, visit www.eurofarma.com.br